403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Eupraxia Pharmaceuticals Inc.
(MENAFN- Baystreet) 08:43 AM EST - Eupraxia Pharmaceuticals Inc.: Announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T are trading unchanged at $10.13.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment